Literature DB >> 29936294

Serotonin and human cancer: A critical view.

Denis Sarrouilhe1, Marc Mesnil2.   

Abstract

Besides its classical functions as a neurotransmitter in the central nervous system, local mediator in the gastrointestinal tract and vasoactive agent in the blood, serotonin has more recently emerged as a growth factor for human tumor cells of different origins (carcinomas, glioma and carcinoids). Several data are also available on serotonin involvement in cancer cell migration, metastatic dissemination and tumor angiogenesis. The serotonin-induced signaling pathways that promote tumor progression are complex and only partly understood in some cancer types. The results of several studies showed that serotonin levels in the tumor played a crucial role in cancer progression. A serotonin production and secretion by neuroendocrine cells have been shown in the progression of several solid tumors and the involvement of a serotoninergic autocrine loop was proposed. Specific receptor subtypes are associated with different fundamental stages of tumor progression and the pattern of receptors expression becomes dysregulated in several human tumors when compared with normal cells or tissues. Serotonin receptors, selective serotonin transporter and serotonin synthesis pathways are potential chemotherapeutic targets for the treatment of several cancers in which therapeutic approaches are limited. Through several asked questions, this critical mini-review discusses the relevance of the involvement of serotonin in human cancer progression.
Copyright © 2018 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Angiogenesis; Carcinogenesis; Chemotherapy; Neuroendocrine cells; SSRI; Serotonin

Mesh:

Substances:

Year:  2018        PMID: 29936294     DOI: 10.1016/j.biochi.2018.06.016

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  32 in total

Review 1.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

2.  Tryptophan metabolism is dysregulated in individuals with Fanconi anemia.

Authors:  Allison L Bartlett; Lindsey Romick-Rosendale; Adam Nelson; Sheyar Abdullah; Nathan Luebbering; Jamen Bartlett; Marion Brusadelli; Joseph S Palumbo; Kelly Lake; Bridget Litts; Alexandra Duell; Annette Urbanski; Adam Lane; Kasiani C Myers; Susanne I Wells; Stella M Davies
Journal:  Blood Adv       Date:  2021-01-12

Review 3.  Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy.

Authors:  Sachin Kumar Deshmukh; Sanjeev Kumar Srivastava; Teja Poosarla; Donna Lynn Dyess; Nicolette Paolaungthong Holliday; Ajay Pratap Singh; Seema Singh
Journal:  Ann Transl Med       Date:  2019-10

4.  Protein signatures to distinguish aggressive from indolent prostate cancer.

Authors:  Fernando Garcia-Marques; Shiqin Liu; Sarah M Totten; Abel Bermudez; Cheylene Tanimoto; En-Chi Hsu; Rosalie Nolley; Amy Hembree; Tanya Stoyanova; James D Brooks; Sharon J Pitteri
Journal:  Prostate       Date:  2022-01-31       Impact factor: 4.104

Review 5.  New Insights on Tramadol and Immunomodulation.

Authors:  Iqira Saeed; Adam La Caze; Markus W Hollmann; Paul N Shaw; Marie-Odile Parat
Journal:  Curr Oncol Rep       Date:  2021-08-27       Impact factor: 5.075

Review 6.  Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment.

Authors:  Francesca Battaglin; Priya Jayachandran; Carly Strelez; Annika Lenz; Sandra Algaze; Shivani Soni; Jae Ho Lo; Yan Yang; Joshua Millstein; Wu Zhang; Evanthia T Roussos Torres; Jean C Shih; Shannon M Mumenthaler; Josh Neman; Heinz-Josef Lenz
Journal:  Oncogene       Date:  2022-10-01       Impact factor: 8.756

Review 7.  Neurotransmitters: emerging targets in cancer.

Authors:  Shu-Heng Jiang; Li-Peng Hu; Xu Wang; Jun Li; Zhi-Gang Zhang
Journal:  Oncogene       Date:  2019-09-16       Impact factor: 9.867

Review 8.  Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.

Authors:  Mengling Wu; Qianrui Huang; Yao Xie; Xuyi Wu; Hongbo Ma; Yiwen Zhang; Yong Xia
Journal:  J Hematol Oncol       Date:  2022-03-12       Impact factor: 17.388

Review 9.  Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.

Authors:  Iwona Kwiatkowska; Justyna Magdalena Hermanowicz; Alicja Przybyszewska-Podstawka; Dariusz Pawlak
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

10.  Identification of Serotonin as a Predictive Marker for Breast Cancer Patients.

Authors:  Qing-E Xie; Xin Du; Mengyao Wang; Fenfen Xie; Zuoyang Zhang; Yunxia Cao; Yajing Liu
Journal:  Int J Gen Med       Date:  2021-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.